Europe’s Pharma Industry Braces for Pain as Trump Tariff Threat Looms

Europe’s Pharma Industry Braces for Pain as Trump Tariff Threat Looms

Trump is softening his tariff talk. But the damage may already be done.

The economic effects of new trade wars could be hard for the United States to dodge even if talks yield new deals soon.

Global Pharma Companies Rush to Invest in U.S., as Trump Administration Examines Tariff on Drug Imports

Pharmaceutical companies around the world, including those in Japan, are expanding investment in the United States. While the country is the world’s largest market for pharmaceuticals, accounting for more than 40% of global sales, U.S. President Donald Trump could soon impose new tariffs on drug imports. Pharma companies are trying to move quickly to minimize the impact of tariffs by adding more production sites in the United States.

BBC Audio | The Inquiry | What is President Trump’s economic plan?

Why Donald Trump has chosen to upend global trading

The economy has begun to cool down and could be heading for a crisis, largely due to the US government's changing but unclear economic and tariff policies, says Gylfi Magnússon, professor of economics at the University of Iceland.

Tariffs backlash may rescue pharma firms

The government is hopeful the tariff threat to Big Pharma companies based here may have eased after what one minister described as Donald Trump’s ‘flirtation with bankruptcy’. The US President this week warned that time is running out for a deal under the 90-day tariff pause. His hard-line Commerce Secretary, Howard Lutnick, also threatened that sector-specific tariffs are on the way. Howard Lutnick. Pic: Andrew Harnik/Getty Images However, the…